Current Oncology, Volume 29, Issue 10
2022 October - 104 articles
Cover Story: The combination of an immune checkpoint inhibitor and a multitarget tyrosine kinase inhibitor has become a standard first-line treatment for metastatic renal cell cancer, changing the therapeutic landscape. Along with survival improvement, combination therapy has raised complexity in adverse event handling. Toxicities could be insidious in clinical presentation, and proper attribution to either of the two classes of drugs could be challenging. Key points that clinicians can rely on to achieve an optimal adverse events management are the adherence to immune-related toxicities’ international guidelines, the application of proper expert-defined algorithms, the knowledge sharing within a multidisciplinary dedicated board, and accurate patient information. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.